Nanobac Pharmaceuticals Book Value Per Share vs. Current Valuation
| NNBP Stock | USD 0.0001 0.00 0.00% |
Book Value Per Share | First Reported 2010-12-31 | Previous Quarter (0.01) | Current Value (0.01) | Quarterly Volatility 0.11099722 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.15 | 0.16 |
|
| |||||
| Operating Profit Margin | 264 | 251 |
|
| |||||
| Return On Equity | 2.63 | 2.51 |
|
|
For Nanobac Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nanobac Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nanobac Pharmaceuticals Incorporated utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nanobac Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nanobac Pharmaceuticals Incorporated over time as well as its relative position and ranking within its peers.
Nanobac |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nanobac Pharmaceuticals. If investors know Nanobac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nanobac Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Revenue Growth 0.866 | Return On Assets (0.37) |
The market value of Nanobac Pharmaceuticals is measured differently than its book value, which is the value of Nanobac that is recorded on the company's balance sheet. Investors also form their own opinion of Nanobac Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Nanobac Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nanobac Pharmaceuticals' market value can be influenced by many factors that don't directly affect Nanobac Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nanobac Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nanobac Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nanobac Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Nanobac Pharmaceuticals Current Valuation vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nanobac Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Nanobac Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Nanobac Pharmaceuticals Incorporated is rated below average in book value per share category among its peers. It is rated below average in current valuation category among its peers . At this time, Nanobac Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Nanobac Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nanobac Current Valuation vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Nanobac Pharmaceuticals |
| = | (0.01) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Nanobac Pharmaceuticals |
| = | 124.75 K |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Nanobac Current Valuation vs Competition
Nanobac Pharmaceuticals Incorporated is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 429.12 Million. Nanobac Pharmaceuticals adds roughly 124,753 in current valuation claiming only tiny portion of equities under Health Care industry.
Nanobac Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nanobac Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nanobac Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Nanobac Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Nanobac Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -5.1 M | -5.4 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Income Before Tax | -7.6 M | -7.9 M | |
| Total Other Income Expense Net | -1.9 M | -1.8 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Net Loss | -7.6 M | -7.9 M | |
| Change To Netincome | 4 M | 2.5 M | |
| Net Loss | (0.02) | (0.02) | |
| Income Quality | 0.12 | 0.19 | |
| Net Income Per E B T | 0.91 | 0.84 |
Nanobac Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nanobac Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nanobac Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nanobac Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Nanobac Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Nanobac Pharmaceuticals position
In addition to having Nanobac Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Value Funds Thematic Idea Now
Small Value Funds
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Nanobac Stock Analysis
When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.